Welcome to our dedicated page for Phreesia news (Ticker: PHR), a resource for investors and traders seeking the latest updates and insights on Phreesia stock.
Phreesia reports developments tied to its patient activation platform for healthcare providers, life sciences companies and other organizations. The company’s recurring news includes quarterly results, stakeholder letters, patient intake, outreach, education and appointment-scheduling solutions, and the scale of patient visits enabled through its digital workflows.
Company updates also cover healthcare payment capabilities, including the completed AccessOne acquisition, credit-facility refinancing, and corporate governance or workplace recognition items. Phreesia’s news flow is centered on software, payments and engagement tools used across healthcare delivery and patient interactions.
Phreesia (NYSE: PHR) announced it will release its fiscal Q1 2023 financial results on June 2, 2022, after market close. A press release and a quarterly stakeholder letter will accompany the results and be available on its investor website. Following the release, the company will hold a conference call at 5:00 PM ET to discuss these results. Phreesia provides healthcare organizations with a SaaS platform for patient intake management, aimed at improving patient engagement and clinical efficiency.
Phreesia has announced that Danielle Lynch, Vice President of Client Experience, is recognized among the 'Women to Watch' by MM+M. This accolade honors influential leaders in healthcare marketing, with Lynch being one of only 25 selected for 2022.
Since Phreesia's IPO in 2019, Lynch has doubled her team and contributed to a nearly 100% increase in Life Sciences revenue, showcasing her innovation and leadership. David Linetsky praised her for building the Client Experience team that drives Phreesia Life Sciences' growth.
Phreesia, Inc. (NYSE: PHR) reported financial results for Q4 and FY 2022, emphasizing a strong revenue growth of 39% year-over-year to $58.0 million in Q4, and 43% growth to $213.2 million for the fiscal year. Despite increased revenues, Adjusted EBITDA was negative $30.5 million for Q4 and negative $59.0 million for the full year. Cash reserves stood at $313.8 million. Looking ahead, the company forecasts FY 2023 revenue between $271 million and $275 million, indicating a growth of 27% to 29%, but expects Adjusted EBITDA to worsen before recovering in FY 2025.
Phreesia, Inc. (NYSE: PHR) will host a conference call on March 30, 2022, at 5:00 p.m. ET to discuss its fiscal fourth quarter 2022 financial results. A press release detailing these results will be issued before the call, following market close on the same day. The company provides a suite of applications to enhance patient intake processes through its innovative SaaS platform, improving patient engagement and clinical care efficiency.
Phreesia (NYSE: PHR) has been named the 2022 Best in KLAS for Patient Intake Management for the fourth consecutive year, highlighting its excellence in healthcare IT services. The award, based on feedback from healthcare providers, recognizes Phreesia's robust platform that automates patient outreach and intake processes, including self-service registration and insurance verification. Phreesia earned a top score of 90.0, demonstrating its commitment to enhance clinical care and efficiency. CEO Chaim Indig emphasized ongoing investment in their platform to support healthcare providers.
Summary not available.
Phreesia has joined MEDITECH Greenfield, a pilot program aimed at fostering app integration with MEDITECH Expanse. This collaboration will enhance patient engagement in their care by enabling API-based integration, notifying patients about preventive care gaps, and reducing barriers to access. CEO Chaim Indig emphasized the importance of interoperability in healthcare, stating this partnership will support the development of innovative solutions for MEDITECH clients. The initiative aims to set an industry standard for interoperability.
Phreesia, listed on NYSE as PHR, has received recognition from PM360, a healthcare marketing publication, for its PatientInsights platform, which was named one of the 2021 Most Innovative Services. This honor reflects PatientInsights' effectiveness in conducting targeted patient surveys before doctor appointments, yielding higher completion rates and reliable data. The platform's integration with electronic health records streamlines survey processes, significantly reducing question counts. Phreesia continues to position itself at the forefront of patient-centric healthcare solutions.
Phreesia has been recognized by Medical Marketing and Media (MM+M) as one of the Best Places to Work 2021 in the healthcare marketing industry. This marks the fourth year of the awards, where Phreesia was highlighted in the 'Large Companies/Service Providers' category, being one of only two companies to receive this honor. Employees praised the company's inclusive culture and benefits, especially its response to COVID-19, which included enhanced pay and support for remote work. The recognition underscores Phreesia's commitment to transforming the patient experience.
Phreesia has acquired Insignia Health, LLC, a company focused on improving health outcomes through patient activation. This acquisition enhances Phreesia's mission to empower patients in their healthcare journey. Insignia holds the exclusive license for the Patient Activation Measure® (PAM®), recognized as the gold standard for assessing patient activation. The integration is expected to broaden PAM's reach, improving patient engagement and outcomes. Phreesia aims to leverage Insignia's expertise to provide more personalized care.